{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"38"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"34"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"28"}],"title":"Progressive disease"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"5"}],"title":"Inevaluable for response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assigned one of the following: Complete Response: Disappearance of all target lesions; Partial Response: ≥30% decrease in the sum of the longest diameters of target lesions; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD; Inevaluable for response: specify reasons (for example: early death, malignant disease, toxicity; tumour assessments not repeated/incomplete; other).\n\nNormally, all eligible patients should be included in the denominator for the calculation of the response rate for phase II trials.","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Treated patients with disease measurement","reportingStatus":"POSTED","timeFrame":"From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)","title":"Response by Investigator Assessment","type":"PRIMARY","unitOfMeasure":"Participants"}